ESR1 and invasive breast carcinoma: A key finding is that a five-biomarker panel consisting of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her2), CK5/6, and epidermal growth factor receptor (EGFR) shows promise in categorizing invasive breast cancers into their corresponding molecular subtypes (Cheang et al.).